We develop a broad portfolio of drug candidates that have the potential to meaningfully improve the lives of patients by directly addressing the causes and risk factors of neurodegenerative diseases.
Each of our programs strictly follows the principles of our R&D strategy: Selecting targets that are genetically linked to the disease, engineering our molecules to cross the blood-brain barrier, and guiding clinical development through the discovery and use of biomarkers.
|LRRK2||Parkinson's||Early Clinical DNL201|
|LRRK2||Parkinson's||Early Clinical DNL151|
|RIPK1||ALS, Alzheimer's, MS||Early Clinical DNL747|
|Iduronate 2-sulfatase||MPS II (Hunter Syndrome)||IND-Enabling DNL310 (ETV:IDS)|
|Alpha-Synuclein||Parkinson's, DLB, MSA||IND-Enabling ATV:aSyn|
|Undisclosed||Neurodegeneration||Drug Discovery LF1|
|TREM2||Alzheimer's||Drug Discovery ATV:TREM2|
|Tau||Alzheimer's||Drug Discovery ATV:Tau|
|Undisclosed||Neurodegeneration||Drug Discovery CH1|
|RIPK1||RA, Psoriasis||IND-Enabling DNL758|